U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Aptorum Group

Market Cap: US$13.2m

Through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases.

Insmed

Market Cap: US$30.1b

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

Kezar Life Sciences

Market Cap: US$28.0m

A clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States.

Akero Therapeutics

Market Cap: US$3.5b

Engages in the development of treatments for patients with serious metabolic diseases in the United States.

Century Therapeutics

Market Cap: US$41.4m

A clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.

Tiziana Life Sciences

Market Cap: US$176.1m

A biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States.

I-Mab

Market Cap: US$500.2m

A biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.

Compugen

Market Cap: US$131.9m

A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

NewAmsterdam Pharma

Market Cap: US$2.9b

A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.

Vera Therapeutics

Market Cap: US$1.4b

A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.

enGene Holdings

Market Cap: US$255.5m

Through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer.

Ocugen

Market Cap: US$321.7m

A biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health.

Rafael Holdings

Market Cap: US$50.9m

Primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel.

Altimmune

Market Cap: US$314.2m

A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.

PolyPid

Market Cap: US$53.2m

A clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.

MaxCyte

Market Cap: US$145.0m

A life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.

Alto Neuroscience

Market Cap: US$95.0m

Operates as a clinical-stage biopharmaceutical company in the United States.

Replimune Group

Market Cap: US$453.5m

A clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.

Immunocore Holdings

Market Cap: US$1.8b

A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.

Belite Bio

Market Cap: US$2.1b

A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.

89bio

Market Cap: US$1.3b

A clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.

Agilent Technologies

Market Cap: US$36.4b

Provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.

Assembly Biosciences

Market Cap: US$362.7m

A biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.

Champions Oncology

Market Cap: US$95.3m

A technology-enabled research company, provides technology solutions for drug discovery and development in the United States.

Arrowhead Pharmaceuticals

Market Cap: US$3.9b

Develops medicines for the treatment of intractable diseases in the United States.

Sol-Gel Technologies

Market Cap: US$78.0m

Together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally.

Pyxis Oncology

Market Cap: US$118.5m

A clinical stage company, engages in the development of therapeutics to treat solid tumors.

Invivyd

Market Cap: US$194.5m

A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.

Incannex Healthcare

Market Cap: US$54.3m

A clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia.

COMPASS Pathways

Market Cap: US$489.3m

Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.

TScan Therapeutics

Market Cap: US$107.3m

A clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.

Gain Therapeutics

Market Cap: US$62.6m

A biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.

Zhengye Biotechnology Holding

Market Cap: US$373.0m

Engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China.

Adlai Nortye

Market Cap: US$64.9m

A clinical-stage biotechnology company, engages in the research and development of pharmaceutical products.

Sana Biotechnology

Market Cap: US$780.9m

A biotechnology company, focuses on utilizing engineered cells as medicines in the United States.

Neuphoria Therapeutics

Market Cap: US$22.4m

A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.